Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC
January 18th 2022Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.
Watch
Interferon Use in Patients with Myeloproliferative Neoplasms
January 11th 2022Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.
Watch